Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Surgery journal (New York, N.Y.) 2018-Oct

Outcomes of Biliointestinal Bypass among Iranian Obese Patients.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Veza se sprema u međuspremnik
Seyed Morteza Mousavi Naeini
Alireza Khalaj
Ali Abbaszadeh-Kasbi
Seyed Rouhollah Miri

Ključne riječi

Sažetak

Background There are several surgical approaches to treat obesity not cured with medical approaches. Each method has its advantages and complications. In here, we have conducted a study to evaluate complications of biliointestinal bypass surgery (BIBP). Methods A prospective study was conducted in a private hospital from 2002 to 2016. Those patients, not previously operated for morbid obesity, were eligible. Mean follow-up period was 89 months ( ± 54 months; range: 73-108 months). Main outcome measures were weight, BMI (body mass index), concentrations of blood lipids and glucose, liver transaminases, and obesity-related comorbidities and complications. Results Twenty-three consecutive patients with morbid obesity, including 16 women (69.7%) and seven men (31.3%) with mean age 38.47 ± 10 years (range: 26-57 years) underwent surgery. At the end of follow-up period, a mean BMI reduction of 12.2 kg/m 2 kg/m 2 ( p < 0.001)] was observed. An excess weight loss (EWL) of 63% ( ± 34) was achieved at the end of the study. Additionally, total cholesterol and triglyceride levels decreased postoperative significantly. The main long-term complications were flatulence (60%), borborygmus (47.8%), mal odorous stool (30.4%), and diarrhea (21.7%). Revision rate was 4.34%. There were no cases with irreversible hepatic injury, deaths due to the surgery, or progressive renal failure. Conclusion BIBP seems to be a safe, easily reversible, and one of valid therapeutic approaches in morbidly obese patients. BIBP has the potential to achieve durable weight loss and offers an improved quality of life.

Pridružite se našoj
facebook stranici

Najkompletnija baza ljekovitog bilja potpomognuta naukom

  • Radi na 55 jezika
  • Biljni lijekovi potpomognuti naukom
  • Prepoznavanje biljaka po slici
  • Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
  • Pročitajte naučne publikacije povezane sa vašom pretragom
  • Pretražite ljekovito bilje po učincima
  • Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima

Google Play badgeApp Store badge